1. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines;Renert-Yuval;Annals of Allergy, Asthma & Immunology,2020
2. NIAMS. Atopic Dermatitis: National Institute of Arthritis and Human Musculoskeletal and Skin Diseases; 2022 [cited 2023 April 9]. Available from: https://www.niams.nih.gov/health-topics/atopic-dermatitis/more-info.
3. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib;Nogueira;Dermatology Practice & Conceptual,2021
4. USFDA. FDA’s Center for Drug Evaluation and Research’s (CDER)12th iteration of the annual report,Advancing Health Through Innovation: New Drug Therapy Approvals 2023 [cited 2023 April 15]. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022.
5. Pfizer. CIBINQO (abrocitinib) Prescribing Information 2023 [cited 2023 April 14]. Available from: https://www.pfizermedicalinformation.com/en-us/patient/cibinqo-0?tab=pi§ion=all.